Abbott Cardiovascular Systems, Inc.

Allergan, Inc.

Hallux Inc.

Jinping Wan

John Joseph Stankus

Dariush Davalian

Florian Ludwig

Katsuyuki Murase

Shubhayu Basu

Syed F A Hossainy

Patrick Michael Hughes

Mikael Trollsas

Ke Wu

Gene Michal

Florian Niklas Ludwig

Hui Liu

Stephen D Pacetti

Robert M Burk

David Frederick Woodward

Paul M Consigny

Michael H Ngo

Thierry Glauser

Michael R Robinson

Danny Thang Dinh

Irina Astafieva

Gyorgy F Ambrus

Jie Shen

Li Zhao

Rachel Bright

Chandrasekar Durairaj

Bozena Zofia Maslanka

Syed Fayaiz Ahmed Hossainy

Ronald W Heil, Jr

Kyle Klein

Syed F Hossainy

Florencia Lim

Evgenia Mandrusov

Fozan El-Nounou

Alazar N Ghebremeskel

Jeffrey T Ellis

Evgenyi Y Shalaev

Yuet Mei Khong

Prem Swaroop Mohanty

Evgenyi Shalaev

Liangxuan Zhang

Hong Ma

Charles Silvis

Troy Carter

Martin Babler

Ayse Zamboglu

Biodegradable intraocular implants with a high loading of a prostamide compound for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Intraocular implant with high loading of a prostamide

Described herein is a solid complex comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter 'Compound 1') and &#x3b3;-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof. 

Solid complex, preparations and uses thereof

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Prostamide-containing intraocular implant

This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.

Drug delivery system and method of treatment of vascular diseases using photodynamic therapy

Disclosed are biodegradable microspheres between 40 &#x3bc;m and 200 &#x3bc;m in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (&#x3e;7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed.

Microsphere drug delivery system for sustained intraocular release

A composition of bioactive agent-loaded micelles with tissue-targeting properties and methods of using the same are disclosed.

Bioactive agent-loaded targeting micelles

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

Sustained release of Apo A-I mimetic peptides and methods of treatment

Microparticle-bioactive agent based treatments for local treatment of diseased tissues/organs are disclosed.

Microparticles for the treatment of disease

The current invention relates to poly(amide) and poly(ester-amide) polymers, coatings including the polymers, and narrow polydispersity drug delivery particles including the polymers.

Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same

The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.

Regional delivery of therapeutic agents for the treatment of vascular diseases

A method of modifying a medical device such as a stent with nano-constructs is disclosed. The method comprises applying a first fluid to the stent; immersing the stent being wet from the first fluid into a second fluid having a suspension of nano-constructs; and removing the stent from the second fluid and allowing the first and second fluid to be removed such that the nano-constructs are carried by the stent for in vivo application of the constructs to a target location of a mammalian subject. The nano-constructs can be attached to the surface of the stent, can be attached to a surface of the coating of the stent, can be embedded into the stent, or can be embedded into the coating.

Medical devices containing biobeneficial particles

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (Apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (Apo A-I) synthetic peptide, or combination of an Apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various Apo A-I mimetic peptides, or endogenous Apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous Apo A-I.

Sustained release of APO A-I mimetic peptides and methods of treatment

Growing community of inventors

Sunnyvale, CA, United States of America

Jinping Wan